The Inhibition of ABCB1/MDR1 or ABCG2/BCRP Enables Doxorubicin to Eliminate Liver Cancer Stem Cells

By
Justin.choi
-
0
113
Scientists explored the role of inhibition of MDR1 or ABCG2 in sensitizing liver cancer stem cells to doxorubicin, the most frequently used chemotherapeutic agent in treating liver cancer.
[Scientific Reports]

Sorry, but the selected Zotpress account can't be found.

Full Article